Clinical trial NCT01493427: Efficacy of Changing to TRAVATAN® From Prior Therapy
Official title: Multi-Center Study Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (0.004% Travoprost) in Patients Previously on Latanoprost 0.005% or Bimatoprost 0.01% Ophthalmic Solution Monotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Open-Angle Glaucoma
Ocular Hypertension
Keywords: Glaucoma
OAG
OHT
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2011-12-16
Enrollment: 202
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of ocular hypertension or open-angle glaucoma in at least one eye.
* Be on either latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy (including BAK-containing generics) for at least four weeks prior to Screening visit.
* Would benefit from a switch to TRAVATAN® Solution without BAK containing Polyquad® Preservative due to tolerability issues, in the opinion of the investigator.
* IOP considered to be safe (in the opinion of the investigator), in both eyes, in such a way that assured clinical stability of vision and the optic nerve throughout the study period.
* Willing to discontinue the use of all other ocular hypotensive medications prior to receiving the study medication for the entire course of the study.
* Best corrected Snellen visual acuity of 6/60 (20/200, 1.0 LogMAR) or better in each eye
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Known medical history of allergy, hypersensitivity, or poor tolerance to any component of the preparations to be used in this study deemed clinically significant in the opinion of the Principal Investigator.
* Any abnormality preventing reliable applanation tonometry in either eye.
* Severe dry eye or related which has been or currently is being treated with the use of punctal plugs, punctal cautery, Restasis®, or topical ocular corticosteroids.
* Any clinically significant, serious, or severe medical condition.
* Intraocular conventional surgery or laser surgery in either eye less than three months prior to Screening Visit.
* Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.
* Progressive retinal or optic nerve disease from any cause.
* Women who are pregnant, lactating.
* Women not using reliable means of birth control.
* Use of any systemic medication known to affect IOP which has not been on stable course for at least 7 days prior to Screening Visit.
* Any clinically significant, serious, or severe medical condition.
* Participation in any other investigational study within 30 days of Screening Visit.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Mean Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline)
timeFrame: Baseline, Week 12
Secondary outcomes:
measure: Percentage of Patients With Target IOP (≤18 mmHg) at 12 Weeks
timeFrame: Week 12
Other outcomes:
Locations:
Study officials:
affiliation: Alcon Research
name: Severine Durier, Pharm.D
role: STUDY_DIRECTOR
References: